Kiadis Pharma N : AFM Certificate of Approval 2nd Supplement February 2021

Certificate of Approval of a Supplement pursuant to Prospectus Regulation (EU)

2017/1129 of the European Parliament and of the Council

To:

Financial Services and Markets Authority, Belgium

From:

Autoriteit Financiële Markten, the Netherlands

We hereby certify that the Supplement detailed below has been drawn up pursuant to Prospectus Regulation (EU) 2017/1129 of the European Parliament and of the Council and was approved by us on 12 February 2021.

Name of Issuer(s):

Kiadis Pharma N.V.

LEI:

724500RS72JYSQJAMW52

Registered Office(s): Amsterdam

Type of Securities (if applicable): Supplement to the simplified prospectus

National Pospectus Identifier: C2101-01281

Details in respect of the Registration document:

Name of Issuer(s):

Kiadis Pharma N.V.

LEI:

724500RS72JYSQJAMW52

Registered Office(s): Amsterdam

National Prospectus Identifier:

33266

Details in respect of the Securities Note:

Name of Issuer(s): Kiadis Pharma N.V.

LEI: 724500RS72JYSQJAMW52

Registered Office(s): Amsterdam

Identifier:

33265

Signed:

For and on behalf of the: Autoriteit Financiële Markten, the Netherlands

Date:

12 February 2021

Attachment:

(1) Supplement